secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-046860
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing
--------------------------------------------------------------------------------

- SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.
- No serious adverse events; all adverse events mild; no Grade 2+ TEAEs; no trial discontinuations.
- Complete α4β7 receptor saturation maintained through Day 57 with single 300mg dose.
- Phase 2 UC platform trial expected to start mid-2025; ~500 subjects, 12-week induction + 38-week maintenance.
- Portfolio maintenance dosing guidance updated to Q3M-Q6M for monotherapies and combinations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/0001628280-24-046860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/syre-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer